2022 World Conference on Lung Cancer (ePosters)-EP08.01-065. Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer

EP08.01-065. Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer

Back to course

Pdf Summary

A recent study aimed to examine the prevalence of non-driver mutations and characterize patients with advanced or metastatic non-small cell lung cancer (NSCLC) who initiated first-line treatment in routine care. The study analyzed data from a US-based database and included a total of 2,999 patients who met the inclusion criteria. The baseline characteristics of the population were described, including gender, age, histology, smoking status, advanced diagnosis, Eastern Cooperative Oncology Group performance status (ECOG PS), PD-L1 status, and site of metastasis. Overall, 185 mutations were detected, with TP53, KRAS, CDKN2A/B, and STK11 being the most prevalent mutations. Prevalence of the mutations did not significantly differ between de novo and recurrent patients. The study provides real-world evidence on the prevalence of non-driver mutations, which has implications for understanding the impact of these mutations on survival outcomes in NSCLC. The findings contribute to a better understanding of this patient population, particularly in terms of tumor biology and potential treatment strategies. The study was funded by Roche, and the authors acknowledge the support of Medical Science Consulting for medical writing services.

Asset Subtitle

Mariano Provencio

Meta Tag

Speaker Mariano Provencio

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

non-driver mutations

metastatic non-small cell lung cancer

first-line treatment

US-based database

prevalence

TP53

KRAS

CDKN2A/B

STK11

real-world evidence